Immunohistochemical Expression of Programmed Death Ligand-1 in Tumour Milieu of Oral Cancer
Annals of Abbasi Shaheed Hospital and Karachi Medical & Dental College, 2020 Objectives: To determine the immunohistochemical expression of PD-L1 in oral squamous cell carcinoma and to correlate it with clinicopathological parameters.
Moomal Aslam Khan +3 more
doaj +1 more source
Immunocompetent murine models for the study of glioblastoma immunotherapy. [PDF]
, 2014 Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in ...
Bloch, Orin +9 more
core +2 more sources
OncoTargets and Therapy, 2014 The aim of this study was to examine whether short hairpin RNA (shRNA) expressing lentiviral particles targeting B7-H1 infection could result in B7-H1 knockdown on dendritic cells (DCs) and to investigate whether B7-H1 silencing could augment the immune function of DCs and further elicit a more potent anti-tumor immune effect against bladder cancer ...
Wang, Shuo +7 more
openaire +4 more sources
B7 costimulation and intracellular indoleamine-2,3-dioxygenase (IDO) expression in peripheral blood of healthy pregnant and non-pregnant women. [PDF]
, 2014 BACKGROUND: B7 costimulatory molecules are expressed on antigen presenting cells (APCs) and are important regulators of T cell activation. We investigated the role of the B7 family of costimulatory molecules in the development of the systemic maternal ...
A Hutloff +30 more
core +2 more sources
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]
, 2016 PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R. +13 more
core +3 more sources
Immune checkpoint inhibitors in renal cell carcinoma [PDF]
, 2017 The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core +1 more source
Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors. [PDF]
, 2013 Glioblastoma multiforme (GBM) is the most common primary brain cancer. Even with aggressive combination therapy, the median life expectancy for patients with GBM remains approximately 14 months.
Jackson, Christopher +5 more
core +1 more source
Biomarker Research, 2020 Background On-target off-tumor toxicity impedes the clinical application of chimeric antigen receptor-modified T cells (CAR-T cells) in the treatment of solid tumors.
Qibin Liao +5 more
doaj +1 more source
Pattern of differential expression of costimulatory molecules in myeloma cell line MM1.R
Revista Médica del Hospital General de México, 2018 T cells constantly recognise and eliminate circulating tumour cells. They require two signals in order to be activated: antigen presentation via TCR, and costimulatory interaction with different surface molecules of the B7 family, which may either ...
A. De la Cruz-Rosas +4 more
doaj +1 more source
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet [PDF]
, 2017 Glioblastoma (GBM) is the most common, and aggressive, primary brain tumor in adults. With a median patient survival of less than two years, GBM represents one of the biggest therapeutic challenges of the modern era.
Dey, Mahua +2 more
core +2 more sources